Pharmacogenomics of Interferon and Ribavirin Treatment in Patients With Chronic Hepatitis C Virus Infection - Full Text View

Pharmacogenomics of Interferon and Ribavirin Treatment in Patients With Chronic Hepatitis C Virus Infection

This study is currently recruiting participants.
Verified by Bayside Health, September 2005

Sponsors and Collaborators:	Bayside Health University of Adelaide
Information provided by:	Bayside Health
ClinicalTrials.gov Identifier:	NCT00164073

Purpose

The purpose of this study is to examine gene expression profiles by DNA microarray in patients who are responders and non-responders to interferon and ribavirin treatment for hepatitis C virus (HCV). Genes involved in inflammation and fibrosis and mediators of the Th-1 lymphocyte response will be looked for. It is hoped that genetic targets for future more effective and less toxic treatments will be identified.

Condition	Intervention
Hepatitis C	Procedure: Liver biopsy

MedlinePlus related topics:

Hepatitis Hepatitis C

Drug Information available for:

Ribavirin Interferon alfa-2b Interferons

U.S. FDA Resources

Study Type:	Observational
Study Design:	Natural History, Longitudinal, Defined Population, Prospective Study

Official Title:	Pharmacogenomics of Interferon and Ribavirin Treatment in Patients With Chronic Hepatitis C Virus Infection

Further study details as provided by Bayside Health:

Estimated Enrollment:	60
Study Start Date:	February 2004
Estimated Study Completion Date:	February 2007

Show Detailed Description

Eligibility

Ages Eligible for Study:	18 Years to 70 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

HCV mono-infection, no coagulopathy and having a liver biopsy for consideration of treatment

Exclusion Criteria:

Infection with HIV or HBV, excess ethanol (EtOH) consumption and other diseases of the liver

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00164073

Contacts


Contact: Mark D Berzsenyi, MBBS	0417 574 015	m.berzsenyi@alfred.org.au

Locations


Australia, Victoria
	Alfred Hospital	Recruiting
	Melbourne, Victoria, Australia, 3181
	Contact: Mark D Berzsenyi, MBBS 0417 574 015 m.berzsenyi@alfred.org.au
	Principal Investigator: Mark D Berzsenyi, MBBS

Sponsors and Collaborators

Bayside Health

University of Adelaide

Investigators


Principal Investigator:	Mark D Berzsenyi, MBBS	The Alfred

More Information

Study ID Numbers:	122/03
First Received:	September 13, 2005
Last Updated:	July 31, 2007
ClinicalTrials.gov Identifier:	NCT00164073
Health Authority:	Australia: Human Research Ethics Committee

Keywords provided by Bayside Health:

HCV and microarray

HCV

Study placed in the following topic categories:

Virus Diseases

Hepatitis

Liver Diseases

Digestive System Diseases

Hepatitis, Chronic

Interferons

Ribavirin

Hepatitis, Viral, Human

Hepatitis C

Interferon Alfa-2b

Hepatitis C, Chronic

Additional relevant MeSH terms:

RNA Virus Infections

Flaviviridae Infections

ClinicalTrials.gov processed this record on October 24, 2008